JD Health International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

JD Health International yıllık ortalama 65.5% oranında kazançlarını artırırken, Consumer Retailing sektöründe kazançlar growing at 15.8% annual. Gelirler growing yılda ortalama 25.8% oranında artmaktadır. JD Health International'in özkaynak karlılığı 5% ve net marjı 4.8%'dir.

Anahtar bilgiler

65.5%

Kazanç büyüme oranı

66.0%

EPS büyüme oranı

Consumer Retailing Sektör Büyümesi	28.3%
Gelir büyüme oranı	25.8%
Özkaynak getirisi	5.0%
Net Marj	4.8%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

JD Health International nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSC:6618 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	54,764	2,618	10,321	1,255
31 Mar 24	54,147	2,380	10,165	1,241
31 Dec 23	53,530	2,142	10,008	1,226
30 Sep 23	53,576	1,930	9,903	1,212
30 Jun 23	53,621	1,718	9,798	1,197
31 Mar 23	50,179	1,049	9,384	1,132
31 Dec 22	46,736	380	8,969	1,067
30 Sep 22	42,003	-7	8,542	1,023
30 Jun 22	37,270	-395	8,114	978
31 Mar 22	33,976	-734	7,911	935
31 Dec 21	30,682	-1,074	7,708	893
30 Sep 21	27,463	-6,702	6,799	813
30 Jun 21	24,243	-12,331	5,890	733
31 Mar 21	21,813	-14,783	4,923	671
31 Dec 20	19,383	-17,234	3,957	609
30 Sep 20	17,007	-11,901	3,346	537
30 Jun 20	14,631	-6,567	2,736	466
31 Mar 20	12,737	-3,769	2,389	402
31 Dec 19	10,842	-972	2,042	338
31 Dec 18	8,169	215	1,458	218
31 Dec 17	5,553	179	1,002	123

Kaliteli Kazançlar: 6618 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 6618 'nin mevcut net kar marjları (4.8%) geçen yılın (3.2%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 6618 son 5 yılda karlı hale geldi ve kazançlarını yıllık 65.5% oranında artırdı.

Büyüme Hızlandırma: 6618 'un son bir yıldaki kazanç büyümesi ( 52.4% ) 5 yıllık ortalamasının ( 65.5% /yıl) altındadır.

Kazançlar vs. Sektör: 6618 geçen yılki kazanç büyümesi ( 52.4% ) Consumer Retailing sektörünün -7.2% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 6618 'nin Özsermaye Getirisi ( 5% ) düşük olarak değerlendiriliyor.

JD Health International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin